Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

212
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
212
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

280
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
280
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

397
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
397
Modified-Release Drug Delivery Systems: Bioavailability01:30

Modified-Release Drug Delivery Systems: Bioavailability

79
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
79
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

257
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
257

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A curated geospatial dataset of chemicals used in hydraulic fracturing and their functions.

Journal of environmental quality·2026
Same author

Report on the 5th and 6th Mystery of Reactive Oxygen Species Conferences.

ALTEX·2026
Same author

Pushing the envelope: Routine operating room extubation in aortic surgery.

JTCVS open·2026
Same author

Migraine, associated treatments and risk of miscarriage: A matched cohort study and nested case-control study using the CPRD pregnancy register.

Cephalalgia : an international journal of headache·2026
Same author

Rising Exception Requests in the Current Heart Allocation System.

JACC. Heart failure·2025
Same author

Reproduction of the human relevant potency threshold (HRPT) for estrogen receptor alpha agonism in an inference performance screen for ICCVAM's regulatory scientific confidence framework.

Frontiers in toxicology·2025
Same journal

The combined impact of chemical and non-chemical stressors on adverse health outcomes: an overview of reviews from the epidemiological literature and experimental animal studies.

Journal of exposure science & environmental epidemiology·2026
Same journal

Diet and mycoestrogen exposure in a pregnancy cohort: the Jersey Babies pilot study.

Journal of exposure science & environmental epidemiology·2026
Same journal

Source apportionment of fine particulate matter (PM<sub>2.5</sub>) personal exposures: findings from the Household Air Pollution Intervention Network (HAPIN) study in rural Guatemala.

Journal of exposure science & environmental epidemiology·2026
Same journal

The impact of geomagnetic disturbances on mortality from respiratory tract infections in the USA, 2000-2019.

Journal of exposure science & environmental epidemiology·2026
Same journal

Metabolome-wide association study identifies metabolites associated with human exposure to perfluoroalkyl substances.

Journal of exposure science & environmental epidemiology·2026
Same journal

Contribution of non-dietary indoor exposure pathways to total phthalate intake of 324 children in Tianjin, China.

Journal of exposure science & environmental epidemiology·2026
See all related articles

Related Experiment Video

Updated: Mar 18, 2026

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging
11:07

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging

Published on: November 24, 2021

3.4K

Generic formulations: availability and applicability for exposure assessment.

Rosemary T Zaleski1, Andreas Ahrens2, Richard A Becker3

  • 1Lumina Consulting L.L.C., Hillsborough, NJ, USA. rzaleski10@gmail.com.

Journal of Exposure Science & Environmental Epidemiology
|March 17, 2026
PubMed
Summary
This summary is machine-generated.

Generic formulations (GFs) aid exposure and risk assessment by standardizing product information. Developing consistent platforms for sharing this data is crucial for industrial product safety evaluations.

Keywords:
Chemical in productsComputational exposure scienceExposure assessmentExposure modelingRisk assessmentSustainable developmentWorkplace exposures

More Related Videos

Assessment of the Acute Inhalation Toxicity of Airborne Particles by Exposing Cultivated Human Lung Cells at the Air-Liquid Interface
10:10

Assessment of the Acute Inhalation Toxicity of Airborne Particles by Exposing Cultivated Human Lung Cells at the Air-Liquid Interface

Published on: February 23, 2020

7.7K
Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
08:25

Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure

Published on: June 5, 2020

7.4K

Related Experiment Videos

Last Updated: Mar 18, 2026

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging
11:07

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging

Published on: November 24, 2021

3.4K
Assessment of the Acute Inhalation Toxicity of Airborne Particles by Exposing Cultivated Human Lung Cells at the Air-Liquid Interface
10:10

Assessment of the Acute Inhalation Toxicity of Airborne Particles by Exposing Cultivated Human Lung Cells at the Air-Liquid Interface

Published on: February 23, 2020

7.7K
Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
08:25

Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure

Published on: June 5, 2020

7.4K

Area of Science:

  • Chemical Risk Assessment
  • Environmental Science
  • Industrial Chemistry

Background:

  • Generic formulations (GFs) represent product compositions by function, not specific chemicals, aiding safety assessments.
  • GFs facilitate sharing of essential screening data without revealing proprietary product details.
  • They provide a structured framework for organizing product types and associated chemical ingredient information.

Purpose of the Study:

  • To explain the utility of Generic Formulations (GFs) in exposure and risk evaluation.
  • To identify sources of GF information, particularly for industrial products.
  • To suggest improvements for GF development and data sharing.

Main Methods:

  • Locating and mapping publicly accessible Generic Formulation (GF) references to OECD harmonized use categories.
  • Utilizing author expertise to identify GF data embedded in various online documents and spreadsheets.
  • Focusing on information relevant to industrial products, an area with limited public data.

Main Results:

  • GF information was identified for 13 out of 20 OECD use categories.
  • Detailed GF data was found for only 20 out of 91 OECD product sub-categories.
  • Significant limitations in data findability and availability were observed across sources.

Conclusions:

  • Highlights the availability of current Generic Formulation (GF) data.
  • Advocates for the systematic development and public accessibility of GF data.
  • Explains the benefits of GF data availability for diverse user sectors.